GCG and obesity disorder: Liraglutide, a glucagon-like peptide-1 (GLP-1) analog acylated with palmitic acid that was originally developed as a type-2 diabetes mellitus (T2DM) drug, has recently been approved in the U.S.A for obesity treatment (Saxenda).